BridgeBio Oncology Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $271.57 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-03-11
- BridgeBio Oncology Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-12-31 was $77.40K.
- BridgeBio Oncology Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $77.40K.
- BridgeBio Oncology Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $77.40K.
- BridgeBio Oncology Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $39.37K.
- BridgeBio Oncology Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $271.57K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2024-12-31 | $77.40K derived: 10-K 12 month − 3 quarters · filed 2025-03-11 | $154.80K derived: sum of 2 quarters · filed 2025-03-11 | $232.20K derived: sum of 3 quarters · filed 2025-03-11 | $271.57K 10-K · filed 2025-03-11 |
| 2024-09-30 | $77.40K 10-Q · filed 2024-11-14 | $154.80K derived: sum of 2 quarters · filed 2024-11-14 | $194.17K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2024-06-30 | $77.40K 10-Q · filed 2024-11-14 | $116.77K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2024-03-31 | $39.37K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |